Skip to content

Benfotiamine

A fat-soluble form of vitamin B1 that reaches tissues far better than regular thiamine — used for nerve health and glycation/blood-sugar complications.

  • CategoryMetabolic & Weight
  • FormFat-soluble B1
  • EvidenceClinical trials on file

Where to get Benfotiamine

iHerb
Fat-soluble B1

Cam’s partner link opens iHerb on this product. No code needed; the link credits Cam.

Shop on iHerb

The short version

  • What it doesBenfotiamine is not a lipid-soluble vitamin, and the correction matters because it changes what the molecule can do. It is S-benzoylthiamine O-monophosphate: an open-ring, neutral, S-acylated derivative.
  • Who it is forNerve health, blood-sugar complications and anti-glycation support.
  • What to watchA fat-soluble thiamine derivative — very well tolerated, with no established toxicity.

How Benfotiamine works

A fat-soluble thiamine derivative with far better tissue penetration than thiamine hydrochloride. It raises thiamine pyrophosphate, which activates transketolase — and that is the key step: transketolase diverts glycolytic intermediates into the pentose phosphate pathway and away from the three routes that cause hyperglycemic damage, being AGE formation, the hexosamine pathway and protein kinase C activation.

Benfotiamine: serving, timing and spacing

Suggested serving
150–300 mg daily.
How often
Daily
When
With food; it is fat-soluble, unlike thiamine

General referenceA general reference intake for education, not a prescription. The label on the product you buy is the final word.

Good to know: The form of B1 to use when nerve or glycation protection is the goal.

Research on Benfotiamine5 evidence notes: clinical, correlative, theoretical

Each note sits under the kind of evidence it stands on. A thin or missing trial means nobody has run it yet, not that it doesn’t work. How the evidence tiers work

Human clinical evidence

  • RCTs support reduced symptoms of diabetic neuropathy and lower AGE (advanced glycation) formation.

  • Far better tissue penetration than water-soluble B1.

Correlative data

  • Glycation damage tracks with diabetic nerve and vascular complications.

Theoretical / extrapolated benefits

  • A lipid-soluble thiamine derivative reaching roughly five times the tissue concentration of thiamine hydrochloride. Mechanistically it activates transketolase, diverting glycolytic intermediates away from the pathways that generate advanced glycation end-products — so the prediction is reduced AGE formation in diabetic tissue.

  • That prediction has been tested and the results are mixed, which is the honest read: the mechanism is clean and the clinical translation is not.

Sources read for this page

  • Volvert ML, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacology 2008 · PMID 18549472
  • Ziegler D. Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy: a randomized, placebo-controlled, double-blind clinical trial (BOND study). BMJ Open Diabetes Res Care 2026 · PMID 41571333
  • Bonhof GJ. BOND study: a randomized double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. BMJ Open 2022 · PMID 35115359
  • Bozic I. Thiamine and benfotiamine: Focus on their therapeutic potential. Heliyon 2023 · PMID 38034619
  • Beltramo E. Thiamine and diabetes: back to the future?. Acta Diabetol 2021 · PMID 34091762
  • Bettendorff L. Synthetic Thioesters of Thiamine: Promising Tools for Slowing Progression of Neurodegenerative Diseases. Int J Mol Sci 2023 · PMID 37511056

Benfotiamine, the deep readThe mechanism, cell to human, which form, how you would know

What Benfotiamine actually does

Benfotiamine is not a lipid-soluble vitamin, and the correction matters because it changes what the molecule can do. It is S-benzoylthiamine O-monophosphate: an open-ring, neutral, S-acylated derivative. Being uncharged, it crosses the intestinal membrane without needing the saturable thiamine transporters, which is the entire point of the molecule. It is then dephosphorylated by alkaline phosphatase at the brush border to S-benzoylthiamine, and the benzoyl group is removed by thioesterases in blood and tissue to release thiamine Volvert 2008.

Where it goes is not where the marketing says. The careful comparison of benfotiamine against genuinely lipid-soluble allithiamine derivatives found different mechanisms and a different pharmacological profile: benfotiamine raises thiamine and thiamine diphosphate strongly in blood, liver and kidney, and much less in brain, because the released thiamine still has to use a transporter to cross the blood-brain barrier Volvert 2008. Sulbutiamine and the thioester series do reach brain Bettendorff 2023. Benfotiamine's advantage is peripheral.

The disease mechanism it was designed for is the transketolase-hyperglycemia hypothesis. Excess intracellular glucose in cells that cannot downregulate their uptake — endothelium, mesangium, neurons — overflows into four damaging routes: the polyol pathway, hexosamine flux, protein kinase C activation by diacylglycerol, and advanced glycation end product formation from methylglyoxal. Activating transketolase diverts fructose-6-phosphate and glyceraldehyde-3-phosphate back into the pentose phosphate pathway and starves all four Beltramo 2021.

That is an elegant hypothesis with a specific enzyme at its center. It predicts that a compound which raises tissue thiamine diphosphate should reduce methylglyoxal-derived advanced glycation end products, and in cell and animal models it does.

The published critique of the mechanism deserves equal billing. Whether transketolase in human tissue is actually thiamine-limited at ordinary status, and whether the enzyme activation achieved in vitro is reproduced at achievable plasma concentrations, has been questioned in the same reviews that describe the therapeutic potential Bozic 2023. An enzyme that is already saturated cannot be activated by more cofactor.

Cell, rodent, human — and where it stops

This page has something almost nothing else in the cohort has: a large, long, well-designed trial that measured the outcome instead of the marker.

In cells and rodents the chain is complete. Benfotiamine raises transketolase activity, reduces hexosamine and protein kinase C flux and prevents experimental retinopathy and neuropathy in diabetic rodents. It is one of the better animal packages in this catalog Beltramo 2021.

In human pharmacokinetics the advantage is real and measured. Benfotiamine produces substantially higher blood thiamine and erythrocyte thiamine diphosphate than an equal oral dose of thiamine hydrochloride, because it bypasses the saturable carrier Volvert 2008. The surrogate the product is sold on genuinely moves, and moves more than the cheap alternative does.

Then somebody ran the trial properly. The BOND study was designed as a 12-month randomized, double-blind, placebo-controlled trial in people with type 2 diabetes and symptomatic polyneuropathy, with morphometric, neurophysiological and clinical measures as endpoints — corneal confocal microscopy nerve fiber measures and intraepidermal nerve fiber density alongside symptom scores Bonhof 2022. That is a design that cannot be satisfied by a biomarker.

The result is the reason this page is in a cohort about surrogates. Over 12 months, benfotiamine did not produce the improvement in the morphometric and neurophysiological measures the trial was built around Ziegler 2026. The compound raised the cofactor, as designed, and the nerves did not respond over a year.

The obstacle to transfer is probably the target, not the delivery. Earlier positive results came from shorter trials with symptom scores as the endpoint, where a subjective measure in a painful condition is vulnerable to placebo response. When the endpoint became a nerve fiber count, the effect did not survive. That is the sequence this whole file is about, and here it happened inside a single well-run program Bonhof 2022 Ziegler 2026.

Benfotiamine — which form, and does it matter

The form IS the drug here, and it is worth being precise about what it is not. Benfotiamine is frequently described as fat-soluble; it is not, particularly. Its aqueous solubility is reasonable and its absorption advantage comes from being uncharged rather than from partitioning into lipid Volvert 2008. The genuinely lipophilic thiamine derivatives are the allithiamines and the synthetic thioesters, and they have a different tissue distribution Bettendorff 2023.

The exposure comparison is the whole commercial case and it is well documented. Against an equal dose of thiamine hydrochloride, benfotiamine gives severalfold higher peak plasma thiamine and markedly higher erythrocyte thiamine diphosphate, with peak plasma concentration at roughly 1 to 2 hours and a longer apparent terminal phase because the S-benzoyl intermediate acts as a slow-release reservoir. Elimination of the released thiamine is by rapid renal clearance once tissue capacity is met Volvert 2008 Bozic 2023.

Two enzymes stand between the tablet and the cofactor, and both can be rate-limiting. Alkaline phosphatase at the brush border removes the phosphate; a thioesterase then hydrolyzes the S-benzoyl bond. Neither step involves a cytochrome, so the usual drug interaction list does not apply, but intestinal alkaline phosphatase activity varies with blood group secretor status, fasting and zinc status, which is an unstudied source of between-person variation.

The doses on the shelf and the doses in the trials are far apart. The BOND program used 300 mg three times daily, 900 mg a day, for twelve months Bonhof 2022. Most retail products are 150 or 300 mg once daily. Somebody buying benfotiamine on the strength of the diabetic neuropathy literature is usually taking a third of the studied dose — and the studied dose is the one that returned null on the hard endpoints.

What benfotiamine is not a substitute for. Because it reaches brain poorly, it is not the derivative to reach for where a central effect is wanted, and it is not appropriate as a replacement for parenteral thiamine in acute Wernicke encephalopathy Volvert 2008.

What would have to be true, and how you would know it was not

1. Predict the cofactor rises, and rises more than on an equal dose of the cheap salt. On 300 mg daily, predict erythrocyte thiamine diphosphate and whole blood vitamin B1 (thiamine) rise measurably within 4 weeks, and by more than 300 mg of thiamine hydrochloride would achieve Volvert 2008. This is the prediction the product will win.

2. Predict the nerve does not change over a year. In symptomatic diabetic polyneuropathy, predict no improvement in intraepidermal nerve fiber density, corneal nerve fiber measures or nerve conduction over 12 months at 900 mg a day, because that is what the trial designed to detect it returned Ziegler 2026 Bonhof 2022. A replication showing morphometric improvement would falsify this page.

3. Predict a symptom score improves and predict you will not be able to interpret it. Neuropathic symptom scales in painful conditions carry large placebo responses over 6 to 12 weeks. Predict an improvement in a self-rated score that is not accompanied by any change in a measured nerve parameter. That dissociation is the content of this page.

4. Predict the glycemic markers do not move. The mechanism is about handling intracellular glucose overflow, not about lowering glucose. Predict HbA1c and fasting insulin unchanged at 12 weeks Beltramo 2021. If HbA1c falls, something else in the regimen changed.

5. The measurement that would rescue the hypothesis. Predict that plasma methylglyoxal-derived advanced glycation end products fall on 900 mg a day. If they do not, the mechanism never engaged and the null endpoint is explained; if they do fall and the nerves still do not recover, the hypothesis was engaged and wrong. Nobody has published that measurement alongside the morphometric endpoints, and it is the single most informative thing left to do Bozic 2023.

What nobody has tested yet

Nobody has tested it early enough. Every trial has enrolled people with established symptomatic neuropathy, where nerve fibers are already lost. Whether benfotiamine prevents neuropathy in people with diabetes and normal nerve function is the question the mechanism actually predicts, and it requires a prevention trial that has never been funded Beltramo 2021.

Nobody knows whether human transketolase is thiamine-limited at all. The activation coefficient in a replete person is small, which implies the enzyme is mostly saturated. If it is, raising thiamine diphosphate further cannot increase flux, and the entire rationale fails at the first step Bozic 2023.

The Alzheimer's signal is a pilot and has stayed one. Small open-label and pilot randomized work with high-dose benfotiamine in mild cognitive impairment has been reported, and the compound reaches brain poorly by design Volvert 2008. Whether a brain-penetrant thioester would do better is an open question with a candidate molecule attached Bettendorff 2023.

And nobody has compared the derivatives head to head in people. Benfotiamine, sulbutiamine and fursultiamine differ in tissue distribution in animals and have never been randomized against each other for any human endpoint. A reader choosing between them is choosing on rodent biodistribution data.

Benfotiamine — its own safety story, not its category's

Tolerability across a year at 900 mg a day was good, and that is a real finding rather than an absence of data. The 12-month randomized program provides safety information at a dose three times what most products supply, with no signal that changed the risk-benefit reading Ziegler 2026 Bonhof 2022. Mild gastrointestinal upset and occasional rash are the usual reports.

The benzoyl group is the part that is not thiamine. Each 300 mg dose delivers a benzoate moiety that is cleaved and handled by conjugation with glycine to hippuric acid for renal excretion. That is an ordinary metabolic route and unremarkable at these doses, but it is the reason benfotiamine is not simply thiamine with better absorption, and it is not characterized in people with impaired renal clearance.

The clinical hazard is what it displaces. Painful polyneuropathy in a person with diabetes warrants an assessment of glycemic control, alcohol intake, B12 status and other causes. A supplement that produces a symptom-score improvement without changing the nerve can delay that work, and the trial evidence says that is the likely pattern Ziegler 2026.

One specific interaction to be aware of. Metformin, the drug most people in this population are taking, both lowers B12 over years and has been reported to interfere with thiamine transport Beltramo 2021. Anyone taking benfotiamine for diabetic neuropathy has a specific reason to have their B12 and methylmalonic acid checked rather than assumed.

Who this is not for. It is not a treatment for acute thiamine deficiency, which needs the parenteral route. It has no safety data in pregnancy or lactation at supplemental doses. And it is not interchangeable with the thiamine on a Supplement Facts panel, in either direction. Nothing here is medical advice or diagnosis, and these statements have not been evaluated by the Food and Drug Administration.

Benfotiamine safety basics3 points of its own

Its own safety story

  • A fat-soluble thiamine derivative — very well tolerated, with no established toxicity.
  • Mild GI upset and, rarely, skin reactions.
  • No significant drug interactions. One of the genuinely benign options in this category.

Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor. Pharmacists are underused and free.

Bloodwork to run5 tests in one order, code CAMERON

Benfotiamine FAQ5 common questions

What is Benfotiamine?
A fat-soluble form of vitamin B1 that reaches tissues far better than regular thiamine — used for nerve health and glycation/blood-sugar complications.
What is the suggested dose of Benfotiamine?
150–300 mg daily. This is a general reference for education only. Statements have not been evaluated by the FDA and this is not medical advice.
Who is Benfotiamine for?
Nerve health, blood-sugar complications and anti-glycation support.
Which labs show whether Benfotiamine is doing anything?
HbA1c (Hemoglobin A1c), Fasting Insulin, Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), TSH (Thyroid-Stimulating Hormone), Vitamin B1 (Thiamine). Draw a baseline before you start, then recheck.
Where can I buy Benfotiamine?
Coach Cam sources Benfotiamine from vetted, top-rated brands on iHerb. Use the buy link on this page.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

The full stack plan is inside Skool

This page covers what Benfotiamine is, what the research says and how people take it. Skool puts it in order alongside everything else you run, peptides included.

Free on this page

What Benfotiamine is and how it works · The serving, its basis, and its safety lines · The research and the bloodwork that shows it

  • What Benfotiamine is and how it works
  • The serving, its basis, and its safety lines
  • The research and the bloodwork that shows it

Members get

  • Benfotiamine in your full stack: what it runs with, and what it cancels out
  • Its place in 2 Protocol Blueprints (Longevity, Metabolic Health), week by week
  • The retest plan: HbA1c (Hemoglobin A1c) baseline, the recheck, what a change means
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational reference only. Not medical advice. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy on iHerbJoin Skool